A Simple Study May Herald a Big Change in Evidence-Based Medicine
Sensible Medicine
JUNE 5, 2023
For instance, in the FOURIER trial, the super-expensive PCSCK9 inhibitor, evolocumab, reduced a primary composite outcome (CV death, MI, Stroke, unstable angina, coronary revascularization) vs placebo. We call this acute ischemic stroke or AIS. The absolute risk decrease was just 1.5%, and it was driven by non-fatal outcomes.
Let's personalize your content